S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-3.32%) $1.920
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

Realaus laiko atnaujinimai Eisai Co., Ltd. [ESALF]

Birža: OTC Sektorius: Healthcare Pramonė: Drug Manufacturers—Specialty & Generic
Atnaujinta25 bal. 2024 @ 20:54

0.00% $ 40.01

Live Chart Being Loaded With Signals

Commentary (25 bal. 2024 @ 20:54):

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures...

Stats
Šios dienos apimtis 4.00
Vidutinė apimtis 1 120.00
Rinkos kapitalizacija 11.48B
EPS $9.72 ( 2023-11-06 )
Last Dividend $0.603 ( 2023-03-30 )
Next Dividend $0 ( N/A )
P/E 39.22
ATR14 $0 (0.00%)

Eisai Co., Ltd. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Eisai Co., Ltd. Finansinės ataskaitos

Annual 2023
Pajamos: $744.40B
Bruto pelnas: $543.48B (73.01 %)
EPS: $193.31
FY 2023
Pajamos: $744.40B
Bruto pelnas: $543.48B (73.01 %)
EPS: $193.31
FY 2022
Pajamos: $756.23B
Bruto pelnas: $569.79B (75.35 %)
EPS: $167.27
FY 2021
Pajamos: $645.94B
Bruto pelnas: $484.63B (75.03 %)
EPS: $146.95

Financial Reports:

No articles found.

Eisai Co., Ltd. Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0.555
(N/A)
$0
(N/A)
$0.603
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Eisai Co., Ltd. Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.00 - Decrease likely (20.04%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend $0.784 2014-03-27
Last Dividend $0.603 2023-03-30
Next Dividend $0 N/A
Payout Date 2018-05-24
Next Payout Date N/A
# dividends 18 --
Total Paid Out $11.60 --
Avg. Dividend % Per Year 0.00% --
Score 2.79 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 4.00
Div. Directional Score 7.04 --
Next Divdend (Est)
(2024-09-23)
$0 Estimate 0.00 %
Dividend Stability
0.09 Very Bad
Dividend Score
2.79
Pay Frequency
Annually
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
WJRYF Ex Dividend Knight 2023-09-28 Annually 0 0.00%
MCBK Ex Dividend Junior 2023-05-02 Annually 0 0.00%
CMSQY Ex Dividend Knight 2023-08-22 Annually 0 0.00%
SOBS Ex Dividend Knight 2023-06-29 Quarterly 0 0.00%
HCMLY Ex Dividend Knight 2023-05-09 Annually 0 0.00%
AMNF Ex Dividend King 2023-07-06 Quarterly 0 0.00%
NLCP Ex Dividend Knight 2023-09-28 Quarterly 0 0.00%
CTUY Ex Dividend Junior 2023-05-24 Annually 0 0.00%
THNPF Ex Dividend Knight 2023-05-22 Annually 0 0.00%
IDCBY Ex Dividend Junior 2023-07-06 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.06061.5008.7910.00[0 - 0.5]
returnOnAssetsTTM0.03461.2008.8510.00[0 - 0.3]
returnOnEquityTTM0.05461.500-0.504-0.756[0.1 - 1]
payoutRatioTTM1.011-1.00010.00-10.00[0 - 1]
currentRatioTTM2.380.8003.102.48[1 - 3]
quickRatioTTM1.6970.8004.723.78[0.8 - 2.5]
cashRatioTTM1.0251.5005.428.12[0.2 - 2]
debtRatioTTM0.127-1.5007.89-10.00[0 - 0.6]
interestCoverageTTM25.361.0001.7191.719[3 - 30]
operatingCashFlowPerShareTTM215.912.0010.0010.00[0 - 30]
freeCashFlowPerShareTTM166.262.0010.0010.00[0 - 20]
debtEquityRatioTTM0.203-1.5009.19-10.00[0 - 2.5]
grossProfitMarginTTM0.7891.0000.1760.176[0.2 - 0.8]
operatingProfitMarginTTM0.07901.000-0.419-0.419[0.1 - 0.6]
cashFlowToDebtRatioTTM0.3721.0009.049.04[0.2 - 2]
assetTurnoverTTM0.5720.8009.527.62[0.5 - 2]
Total Score10.08

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM39.991.0006.060[1 - 100]
returnOnEquityTTM0.05462.50-0.324-0.756[0.1 - 1.5]
freeCashFlowPerShareTTM166.262.0010.0010.00[0 - 30]
dividendYielPercentageTTM0.01681.5009.580[0 - 0.4]
operatingCashFlowPerShareTTM215.912.0010.0010.00[0 - 30]
payoutRatioTTM1.0111.50010.00-10.00[0 - 1]
pegRatioTTM0.01621.500-3.230[0.5 - 2]
operatingCashFlowSalesRatioTTM0.08261.000-0.4340[0.1 - 0.5]
Total Score4.00

Eisai Co., Ltd.

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Apie Signalai gyvai

Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.

Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.